Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904579 · ClinicalTrials.gov registry record
Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 19,929,901
- Enrollment target
NCT00904579: Completed study, sponsored by National Cancer Institute (NCI).
NCT00904579 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 19,929,901 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904579 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 19,929,901 participants
- Enrollment target
Study Summary
Background: * Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression * End-stage renal disease (ESRD), the most common type of end-stage organ disease leading to transplant, is itself linked to increased risk for some cancers * The role of immunosuppression and other factors causing cancer in this setting are not fully understood. Objectives: * To characterize cancer risk in transplant recipients and identify risk factors. * To characterize risk for transmission of cancer from organ donors to recipients. * To describe cancer risk in ESRD. Eligibility: Patients are not required for this study. Data are gathered from existing databases of ESRD patients, organ transplant patients and cancer registries. Design: * Databases of 1) U.S. transplant recipients, donors and wait list candidates and 2) U.S. ESRD patients will be linked to multiple U.S. cancer registries to identify cancers in transplant recipients and ESRD patients. * The spectrum of cancer risk in transplant recipients and ESRD patients will be evaluated in detail. * The cancer risk in transplant recipients will be examined in relation to whether the donors had cancer. * The proposed cancer risk factors (e.g., underlying medical condition, infection with cancer-causing viruses, immunosuppressive medications) documented in transplant and ESRD files will be studied for association with increased risk of particular types of cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19,929,901 participants |
| Start Date | 2006-07-01 |
| Est. Completion | 2020-04-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00904579
The ClinicalTrials.gov registry entry for NCT00904579 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19,929,901 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00904579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00904579 about?
NCT00904579 is a clinical study titled "Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease". Background: * Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression * End-stage renal disease (ESRD), the most common type of end-stage organ disease leading to trans...
What is the current status of trial NCT00904579?
This trial is currently completed. The enrollment target is 19,929,901 participants. The study started on 2006-07-01. Estimated completion is 2020-04-22.
Who is sponsoring clinical trial NCT00904579?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.